No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Quantitative shorting framework for distressed biotech stocks
A quantitative screening framework focused on cash runway and balance sheet metrics can systematically identify failing biotech companies for shorting.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.